We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+23.8%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$239M
AUM Growth
+$38.5M
Cap. Flow
+$5.11M
Cap. Flow %
2.14%
Top 10 Hldgs %
60.96%
Holding
53
New
9
Increased
15
Reduced
7
Closed
12
Avg Time Held
3.7 quarters
Top 10 Avg Time Held
2.1 quarters
Top 20 Avg Time Held
3.2 quarters

Top Buys

Rank Stock Value
1
ARDX icon
Ardelyx
ARDX
+$4.64M
2
CORI
Corium International, Inc.
CORI
+$3.29M
3
XLRN
Acceleron Pharma
XLRN
+$2.9M
4
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$2.83M
5
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$2.55M

Top Sells

Rank Stock Value
1
TVRD icon
Tvardi Therapeutics
TVRD
+$7.08M
2
OCUL icon
Ocular Therapeutix
OCUL
+$5.1M
3
SAGE icon
Sage Therapeutics
SAGE
+$3.2M
4
GNMX icon
Aevi Genomic Medicine Inc
GNMX
+$1.99M
5
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$1.96M

Sector Composition

Rank Sector Weight
1 Healthcare 98.92%
2 Miscellaneous 1.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TTPH
26
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.35M 0.98%
+16,500
New +$2.55M
2017 Q2
0 quarters
WVE icon
27
Wave Life Sciences
WVE
$619M
$2.33M 0.97%
125,000
+46,700
+60% +$1.01M
2017 Q1
1 quarter
PETX
28
DELISTED
Aratana Therapeutics, Inc.
PETX
$2.28M 0.95%
+350,200
New +$2.15M
2017 Q2
0 quarters
XOMA icon
29
DELISTED
Xoma
XOMA
$2.22M 0.93%
317,200
+276,800
+685% +$1.84M
2017 Q1
1 quarter
SYBX icon
30
DELISTED
Synlogic
SYBX
$1.92M 0.8%
+10,934
New +$2.02M
2017 Q2
0 quarters
SYRS icon
31
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.76M 0.74%
10,950
+8,435
+335% +$1.33M
2017 Q1
1 quarter
ZSAN
32
DELISTED
Zosano Pharma Corporation
ZSAN
$1.73M 0.72%
1,750
-36
-2% -$37.2K
2017 Q1
1 quarter
TNXP icon
33
Tonix Pharmaceuticals
TNXP
$105M
– –
0
– –
2017 Q1
1 quarter
PDSB icon
34
PDS Biotechnology
PDSB
$116M
$1.33M 0.56%
6,500
-7,500
-54% -$1.48M
2016 Q1
5 quarters
ARQL
35
DELISTED
Arqule Inc
ARQL
$1.2M 0.5%
970,000
+410,000
+73% +$447K
2017 Q1
1 quarter
GBT
36
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.09M 0.46%
+40,000
New +$1.19M
2017 Q2
0 quarters
VIRX icon
37
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.03M 0.43%
10,857
-4,857
-31% -$558K
2017 Q1
1 quarter
NEOS
38
DELISTED
Neos Therapeutics, Inc
NEOS
$365K 0.15%
+50,000
New +$378K
2017 Q2
0 quarters
BLRX icon
39
BioLineRX
BLRX
$10.8M
$212K 0.09%
417
– –
2013 Q4
14 quarters
ABEO icon
40
Abeona Therapeutics
ABEO
$258M
– –
-11,000
Closed -$1.38M –
CDTX icon
41
DELISTED
Cidara Therapeutics
CDTX
– –
-6,125
Closed -$955K –
IOVA icon
42
Iovance Biotherapeutics
IOVA
$6.57B
– –
-230,000
Closed -$1.71M –
KPTI icon
43
Karyopharm Therapeutics
KPTI
$9.69M
– –
-4,000
Closed -$770K –
NGNE icon
44
Neurogene
NGNE
$431M
– –
-4,250
Closed -$1.42M –
OCUL icon
45
Ocular Therapeutix
OCUL
$1.59B
– –
-550,000
Closed -$5.1M –
SAGE icon
46
DELISTED
Sage Therapeutics
SAGE
– –
-45,000
Closed -$3.2M –
XENE icon
47
Xenon Pharmaceuticals
XENE
$3.33B
– –
-360,000
Closed -$1.44M –
TVRD icon
48
Tvardi Therapeutics
TVRD
$13.9M
– –
-10,694
Closed -$7.08M –
ALBO
49
DELISTED
Albireo Pharma Inc
ALBO
– –
-36,500
Closed -$876K –
PTLA
50
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-50,000
Closed -$1.96M –
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2017 Portfolio in Review

As of Q2 2017, Opaleye Management held 53 positions worth $239M, up 19% from $201M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Opaleye Management's Q2 2017 filing shows 9 new, 15 increased, 7 reduced and 12 closed positions. Its largest new stake was Ardelyx: 546,500 shares worth $2.79M. The largest sale was Tvardi Therapeutics, an estimated $7.08M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q2 2017 buy was Ardelyx: 546,500 shares worth $2.79M.
  • Opaleye Management added most to Corium International, Inc. in Q2 2017, an estimated $3.29M increase.
  • Opaleye Management's biggest Q2 2017 reduction was PDS Biotechnology, cutting an estimated $1.48M.
  • Opaleye Management fully exited Tvardi Therapeutics in Q2 2017, selling an estimated $7.08M.
  • Opaleye Management's ten largest holdings make up 61% of its $239M portfolio in Q2 2017.
  • Opaleye Management opened 9 new positions and closed 12 in Q2 2017.
  • Opaleye Management's portfolio value rose 19% quarter-over-quarter to $239M.

Based on Opaleye Management's 13F filing for Q2 2017, filed 14 Aug 2017.